Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is a clinical-stage neuromuscular disease company with a promising drug platform and a strong pipeline of potential treatments. However, the company faces significant risks in terms of protecting its intellectual property and competing against larger, more established companies in the gene therapy/oligonucleotide medicines space. With a cash balance expected to provide operational runway into 2028, Dyne's potential to become a leader in the market is high, but regulatory and clinical risks must be carefully managed. An NPV analysis projects a 12-month price target of $38 per share by considering future revenue from commercial sales and applying probabilities of success to the company's various pipeline assets.

Bears say

Dyne Therapeutics is a clinical-stage neuromuscular disease company focused on discovering and advancing therapeutics for genetically driven diseases. However, despite their innovative FORCE platform and potential treatments for serious conditions like DM1, DMD, and FSHD, the Company is facing major competition in the biotech and pharmaceutical industries, which possess greater resources, experience and could render their products obsolete. Additionally, Dyne is a development stage company that currently has no revenue, meaning they are reliant on external financing, which could be difficult to obtain. As a financial analyst, it is necessary to consider these factors in a negative outlook for Dyne's stock.

Dyne Therapeutics (DYN) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 13 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Jun 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.